Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb.

Lu P, Qu X, Shen Y, Jiang Z, Wang P, Zeng H, Ji H, Deng J, Yang X, Li X, Lu H, Zhu H.

Sci Rep. 2016 Apr 12;6:24100. doi: 10.1038/srep24100.

2.

The effects of cocaine on HIV transcription.

Tyagi M, Weber J, Bukrinsky M, Simon GL.

J Neurovirol. 2016 Jun;22(3):261-74. doi: 10.1007/s13365-015-0398-z. Epub 2015 Nov 16. Review.

PMID:
26572787
3.

Central memory CD4+ T cells are preferential targets of double infection by HIV-1.

Haqqani AA, Marek SL, Kumar J, Davenport M, Wang H, Tilton JC.

Virol J. 2015 Nov 11;12:184. doi: 10.1186/s12985-015-0415-0.

4.

Epigenetic control of HIV-1 post integration latency: implications for therapy.

Kumar A, Darcis G, Van Lint C, Herbein G.

Clin Epigenetics. 2015 Sep 24;7:103. doi: 10.1186/s13148-015-0137-6. eCollection 2015. Review.

5.

Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus.

Méndez C, Ahlenstiel CL, Kelleher AD.

World J Virol. 2015 Aug 12;4(3):219-44. doi: 10.5501/wjv.v4.i3.219. Review.

6.

The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.

Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST.

MBio. 2015 Jul 7;6(4):e00465. doi: 10.1128/mBio.00465-15.

7.

H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.

Tripathy MK, McManamy ME, Burch BD, Archin NM, Margolis DM.

J Virol. 2015 Aug;89(16):8392-405. doi: 10.1128/JVI.00572-15. Epub 2015 Jun 3.

8.

Progress and challenges in the use of latent HIV-1 reactivating agents.

Shang HT, Ding JW, Yu SY, Wu T, Zhang QL, Liang FJ.

Acta Pharmacol Sin. 2015 Aug;36(8):908-16. doi: 10.1038/aps.2015.22. Epub 2015 Jun 1. Review.

9.

Targeting HIV transcription: the quest for a functional cure.

Mousseau G, Mediouni S, Valente ST.

Curr Top Microbiol Immunol. 2015;389:121-45. doi: 10.1007/82_2015_435. Review.

10.

Short chain fatty acids potently induce latent HIV-1 in T-cells by activating P-TEFb and multiple histone modifications.

Das B, Dobrowolski C, Shahir AM, Feng Z, Yu X, Sha J, Bissada NF, Weinberg A, Karn J, Ye F.

Virology. 2015 Jan 1;474:65-81. doi: 10.1016/j.virol.2014.10.033. Epub 2014 Nov 14.

11.

Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences.

Aiamkitsumrit B, Dampier W, Martin-Garcia J, Nonnemacher MR, Pirrone V, Ivanova T, Zhong W, Kilareski E, Aldigun H, Frantz B, Rimbey M, Wojno A, Passic S, Williams JW, Shah S, Blakey B, Parikh N, Jacobson JM, Moldover B, Wigdahl B.

PLoS One. 2014 Sep 29;9(9):e107389. doi: 10.1371/journal.pone.0107389. eCollection 2014.

12.

Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1.

Hill AL, Rosenbloom DI, Fu F, Nowak MA, Siliciano RF.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13475-80. doi: 10.1073/pnas.1406663111. Epub 2014 Aug 5. Erratum in: Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15598.

13.

The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.

Lucera MB, Tilton CA, Mao H, Dobrowolski C, Tabler CO, Haqqani AA, Karn J, Tilton JC.

J Virol. 2014 Sep;88(18):10803-12. doi: 10.1128/JVI.00320-14. Epub 2014 Jul 9.

14.

Interplay of Rad51 with NF-κB pathway stimulates expression of HIV-1.

Kaminski R, Wollebo HS, Datta PK, White MK, Amini S, Khalili K.

PLoS One. 2014 May 21;9(5):e98304. doi: 10.1371/journal.pone.0098304. eCollection 2014.

15.

Making a Short Story Long: Regulation of P-TEFb and HIV-1 Transcriptional Elongation in CD4+ T Lymphocytes and Macrophages.

Ramakrishnan R, Chiang K, Liu H, Budhiraja S, Donahue H, Rice AP.

Biology (Basel). 2012 Jun 15;1(1):94-115. doi: 10.3390/biology1010094.

16.

Polymicrobial infection and bacterium-mediated epigenetic modification of DNA tumor viruses contribute to pathogenesis.

Doolittle JM, Webster-Cyriaque J.

MBio. 2014 Apr 29;5(3):e01015-14. doi: 10.1128/mBio.01015-14. Review.

17.

Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat.

Jadlowsky JK, Wong JY, Graham AC, Dobrowolski C, Devor RL, Adams MD, Fujinaga K, Karn J.

Mol Cell Biol. 2014 Jun;34(11):1911-28. doi: 10.1128/MCB.01013-13. Epub 2014 Mar 17.

18.

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, Kearney MF, Anderson EM, Coffin JM, Strain MC, Richman DD, Robertson KR, Kashuba AD, Bosch RJ, Hazuda DJ, Kuruc JD, Eron JJ, Margolis DM.

J Infect Dis. 2014 Sep 1;210(5):728-35. doi: 10.1093/infdis/jiu155. Epub 2014 Mar 11.

19.

Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.

Manson McManamy ME, Hakre S, Verdin EM, Margolis DM.

Antivir Chem Chemother. 2014 Jan 29;23(4):145-9. doi: 10.3851/IMP2551. Review.

20.

Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells.

Shan L, Xing S, Yang HC, Zhang H, Margolick JB, Siliciano RF.

J Antimicrob Chemother. 2014 Jan;69(1):28-33. doi: 10.1093/jac/dkt338. Epub 2013 Sep 1.

Items per page

Supplemental Content

Write to the Help Desk